Melatonin in liver resection: first clinical data

Nickkholgh, Arash; Schneider, H; Sobirey, Michael; Venetz, Werner; Nguyen, Huu Son; Bruns, Helge; Weigand, Markus A.; Zorn, Markus; Mw, Büchler; Schemmer, Peter

doi:10.1055/s-0030-1263554

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within the context of the current knowledge of the immunomodulatory effects of melatonin and its role in the gastrointestinal physiology, especially considering the high-affinity binding sites in hepatocyte nuclei, the rationale of this study was to meet the need for a randomized controlled trial to evaluate the safety and efficacy, and the possible benefits of oral administration of melatonin in liver surgery [12]. Preliminary results have been published elsewhere [13].…”

Section: Introductionmentioning

confidence: 99%

The use of high‐dose melatonin in liver resection is safe: first clinical experience

Nickkholgh

Schneider²,

Sobirey³

et al. 2011

Journal of Pineal Research

101

View full text Add to dashboard Cite

Experimental data suggest that melatonin decreases inflammatory changes after major liver resection, thus positively influencing the postoperative course. To assess the safety of a preoperative single dose of melatonin in patients undergoing major liver resection, a randomized controlled double-blind pilot clinical trial with two parallel study arms was designed at the Department of General and Transplantation Surgery, Ruprecht-Karls-University, Heidelberg. A total of 307 patients, who were referred for liver surgery, were screened. One hundred and thirteen patients, for whom a major liver resection (≥3 segments) was scheduled, were eligible. Sixty-three eligible patients refused to participate, and therefore, 50 patients were randomized. A preoperative single dose of melatonin (50 mg/kg BW) dissolved in 250 mL of milk was administered through the gastric tube after the intubation for general anesthesia. Controls were given the same amount of microcrystalline cellulose. Primary endpoint was safety. Secondary endpoints were postoperative complications. Melatonin was effectively absorbed with serum concentrations of 1142.8 ± 7.2 ng/mL (mean ± S.E.M.) versus 0.3 ± 7.8 ng/mL in controls (P < 0.0001). Melatonin treatment resulted in lower postoperative transaminases over the study period (P = 0.6). There was no serious adverse event in patients after melatonin treatment. A total of three infectious complications occurred in either group. A total of eight noninfectious complications occurred in five control patients, whereas three noninfectious complications occurred in three patients receiving preoperative melatonin (P = 0.3). There was a trend toward shorter ICU stay and total hospital stay after melatonin treatment. Therefore, a single preoperative enteral dose of melatonin is effectively absorbed and is safe and well tolerated in patients undergoing major liver surgery.

show abstract

Section: Introductionmentioning

confidence: 99%